Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2018-10-31 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–September 2018. It contains comprehensive financial statements, including income statements, revenue breakdowns by product, and management commentary on business performance. It is clearly a substantive financial report for a period shorter than a full fiscal year, not an announcement or a summary. 9M 2018
2018-10-31 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – SEPTEMBER 2018' and contains comprehensive financial statements, including income statements, revenue breakdowns by business area, and management commentary on performance for the third quarter and the first nine months of the year. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. 9M 2018
2018-10-31 English
Results from the anaGO study – a phase 2 study with anakinra in patients with acute gout
Regulatory Filings Classification · 92% confidence The document announces the 'primary efficacy results' from a Phase 2 clinical study ('anaGO study') involving the drug anakinra for acute gout. It details the study design, endpoints, safety profile, and next steps (meeting with the FDA for Phase 3 planning). This content is a scientific/clinical update regarding drug development and trial outcomes, which is not explicitly covered by the standard financial filing codes (10-K, ER, IR, etc.). Since it is a specific announcement about clinical trial results and future regulatory steps, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the narrative format announcing results, RNS serves as the most appropriate general regulatory announcement category when a more specific clinical trial result code is unavailable. It is not a formal financial report (10-K, IR) or a management discussion (MDA). Given the context of a company releasing specific study results, RNS is the best fit as a general regulatory disclosure.
2018-10-03 English
Resultat från anaGO-studien - en fas 2 studie med anakinra i patienter med akut gikt
Earnings Release Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the main results from a Phase 2 clinical study (anaGO study) regarding the drug anakinra for acute gout. It details the primary endpoint results, safety profile, and plans to meet with the FDA regarding Phase 3. This type of announcement, focusing on key clinical trial results and immediate next steps, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific announcement of clinical trial results rather than a comprehensive financial report (10-K or IR) or a general transcript (CT), and it is a formal announcement of material information, it fits best under the Earnings Release (ER) category, which often includes operational and clinical milestones alongside financial updates, or potentially Regulatory Filings (RNS) if it were less focused on results. Given the focus on study results and the structure of a press release, ER is the most appropriate fit for material operational/clinical news release. FY 2018
2018-10-03 Swedish
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated August 31, 2018, titled "Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)" (Change in the number of shares and votes in Swedish Orphan Biovitrum AB (publ)). The core content details an increase in the total number of shares due to the conversion of C-shares into common shares, resulting from an incentive program. This directly relates to changes in the company's capital structure and share count. This aligns best with the 'Share Issue/Capital Change' category (SHA), which covers announcements regarding new share issues or capital changes. It is not a general regulatory filing (RNS) because it is highly specific to capital structure, nor is it a dividend notice (DIV) or director dealing (DIRS).
2018-08-31 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated August 31, 2018, announcing a change in the total number of shares and votes due to the issuance and subsequent conversion of class C shares into common shares. This directly relates to a change in the company's capital structure (share count). Based on the definitions, the most appropriate category is 'Share Issue/Capital Change' (SHA), as it details the resulting share count after an issuance event. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a dividend notice (DIV) or director dealing (DIRS).
2018-08-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.